Imunon (IMNN) Competitors

$2.74 +0.01 (+0.18%)

As of 01:55 PM Eastern

IMNN vs. MIRA, ELUT, ATRA, LITS, and TAOX

Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include MIRA Pharmaceuticals (MIRA), Elutia (ELUT), Atara Biotherapeutics (ATRA), Lite Strategy (LITS), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry.

How does Imunon compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Imunon had 3 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Imunon and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.44 beat Imunon's score of 0.47 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon has a consensus price target of $132.50, indicating a potential upside of 4,744.61%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Imunon has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

MIRA Pharmaceuticals' return on equity of -210.90% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%
Imunon	N/A	-406.71%	-157.02%

Summary

MIRA Pharmaceuticals beats Imunon on 6 of the 11 factors compared between the two stocks.

How does Imunon compare to Elutia?

Elutia (NASDAQ:ELUT) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Elutia has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.90	$53.38M	$0.82	1.37
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

Elutia has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Imunon has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

74.0% of Elutia shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Elutia presently has a consensus target price of $6.00, suggesting a potential upside of 435.71%. Imunon has a consensus target price of $132.50, suggesting a potential upside of 4,744.61%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Imunon had 4 more articles in the media than Elutia. MarketBeat recorded 5 mentions for Imunon and 1 mentions for Elutia. Elutia's average media sentiment score of 1.89 beat Imunon's score of 0.47 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Very Positive
Imunon	Neutral

Elutia has a net margin of 282.63% compared to Imunon's net margin of 0.00%. Elutia's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	282.63%	N/A	-49.57%
Imunon	N/A	-406.71%	-157.02%

Summary

Elutia beats Imunon on 11 of the 14 factors compared between the two stocks.

How does Imunon compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Atara Biotherapeutics has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.70	$32.69M	$3.12	3.19
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

Atara Biotherapeutics has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, Imunon has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 4.43%. Imunon has a consensus target price of $132.50, suggesting a potential upside of 4,744.61%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has a net margin of 27.07% compared to Imunon's net margin of 0.00%. Atara Biotherapeutics' return on equity of -79.12% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	27.07%	-79.12%	87.55%
Imunon	N/A	-406.71%	-157.02%

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 28 more articles in the media than Imunon. MarketBeat recorded 33 mentions for Atara Biotherapeutics and 5 mentions for Imunon. Imunon's average media sentiment score of 0.47 beat Atara Biotherapeutics' score of 0.07 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atara Biotherapeutics beats Imunon on 10 of the 13 factors compared between the two stocks.

How does Imunon compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Imunon (NASDAQ:IMNN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Imunon has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

In the previous week, Imunon had 4 more articles in the media than Lite Strategy. MarketBeat recorded 5 mentions for Imunon and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat Imunon's score of 0.47 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Overall Sentiment
Lite Strategy	Very Positive
Imunon	Neutral

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lite Strategy's return on equity of -68.86% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-68.86%	-67.48%
Imunon	N/A	-406.71%	-157.02%

Imunon has lower revenue, but higher earnings than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

Imunon has a consensus target price of $132.50, indicating a potential upside of 4,744.61%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Imunon beats Lite Strategy on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Imunon (NASDAQ:IMNN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Imunon has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	149.52	-$28.74M	-$17.14	N/A
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

Synaptogenix's return on equity of -193.08% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-193.08%	-144.93%
Imunon	N/A	-406.71%	-157.02%

Synaptogenix has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Imunon has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Imunon has a consensus target price of $132.50, suggesting a potential upside of 4,744.61%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Imunon had 4 more articles in the media than Synaptogenix. MarketBeat recorded 5 mentions for Imunon and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.89 beat Imunon's score of 0.47 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Very Positive
Imunon	Neutral

Summary

Imunon beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.89M	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-0.34	15.30	20.55	25.41
Price / Sales	N/A	303.37	545.88	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	1.19	6.85	9.62	6.65
Net Income	-$14.49M	$24.11M	$3.55B	$333.40M
7 Day Performance	-1.26%	-1.57%	-0.36%	-0.58%
1 Month Performance	-6.34%	3.83%	5.99%	7.66%
1 Year Performance	-77.65%	71.34%	38.59%	35.36%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	2.1494 of 5 stars	$2.74 +0.2%	$132.50 +4,744.6%	-77.7%	$10.89M	N/A	N/A	30	News Coverage Earnings Report
MIRA MIRA Pharmaceuticals	1.0431 of 5 stars	$1.02 -1.0%	N/A	-18.9%	$43.28M	N/A	N/A	2	Positive News
ELUT Elutia	3.4555 of 5 stars	$0.98 -3.4%	$6.00 +514.9%	-49.0%	$43.21M	$12.29M	N/A	180	Positive News Upcoming Earnings High Trading Volume
ATRA Atara Biotherapeutics	1.6382 of 5 stars	$4.76 -2.5%	$6.00 +26.1%	+20.8%	$41.54M	$120.77M	1.53	330	Trending News Insider Trade Gap Up
LITS Lite Strategy	0.6658 of 5 stars	$1.14 flat	N/A	N/A	$41.45M	$65.30M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. MIRA, ELUT, ATRA, LITS, and TAOX

How does Imunon compare to MIRA Pharmaceuticals?

Summary

How does Imunon compare to Elutia?

Summary

How does Imunon compare to Atara Biotherapeutics?

Summary

How does Imunon compare to Lite Strategy?

Summary

How does Imunon compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. MIRA, ELUT, ATRA, LITS, and TAOX

How does Imunon compare to MIRA Pharmaceuticals?

Which has higher valuation and earnings, MIRA or IMNN?

Do institutionals and insiders believe in MIRA or IMNN?

Does the media favor MIRA or IMNN?

Do analysts recommend MIRA or IMNN?

Which has more risk & volatility, MIRA or IMNN?

Is MIRA or IMNN more profitable?

Summary

How does Imunon compare to Elutia?

Which has preferable valuation & earnings, ELUT or IMNN?

Which has more risk and volatility, ELUT or IMNN?

Do institutionals & insiders have more ownership in ELUT or IMNN?

Do analysts prefer ELUT or IMNN?

Does the media prefer ELUT or IMNN?

Is ELUT or IMNN more profitable?

Summary

How does Imunon compare to Atara Biotherapeutics?

Which has higher earnings and valuation, ATRA or IMNN?

Which has more volatility & risk, ATRA or IMNN?

Do analysts rate ATRA or IMNN?

Is ATRA or IMNN more profitable?

Do institutionals & insiders hold more shares of ATRA or IMNN?

Does the media prefer ATRA or IMNN?

Summary

How does Imunon compare to Lite Strategy?

Which has more risk & volatility, LITS or IMNN?

Does the media favor LITS or IMNN?

Do institutionals and insiders hold more shares of LITS or IMNN?

Is LITS or IMNN more profitable?

Which has preferable valuation & earnings, LITS or IMNN?

Do analysts prefer LITS or IMNN?

Summary

How does Imunon compare to Synaptogenix?

Which has preferable valuation and earnings, TAOX or IMNN?

Is TAOX or IMNN more profitable?

Which has more risk and volatility, TAOX or IMNN?

Do insiders & institutionals believe in TAOX or IMNN?

Do analysts rate TAOX or IMNN?

Does the media favor TAOX or IMNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools